

ISEMBYLD™

(apitegromab-mstn) injection
150mg/3mL

**The first and only
muscle-targeted
treatment in SMA**

ISEMBYLD Is Available via a Limited Specialty Distribution Network

Product and Ordering Information

NDC	84717-150-01 (150 mg/3 mL vial)	Specialty Distributor**	CuraScript SD Phone: 877-900-9223 Fax: 866-628-8942 Email: Wholesalefax@curascript.com https://curascriptsd.com/
How Supplied	ISEMBYLD injection is a sterile, preservative-free, clear to moderately opalescent, colorless to slightly yellow solution supplied in a single-dose glass vial for intravenous use.		
Storage and Handling Requirements	Store ISEMBYLD vials in a refrigerator between 2 °C to 8 °C (36 °F to 46 °F) in the original carton to protect from light. Do not freeze. Do not shake. Discard unused portion.	Specialty Pharmacies**	Accredo Specialty Pharmacy Phone: 877-848-6953 Fax: 888-454-8488 https://www.accredo.com/
Shipping Container Information	Carton dimensions: 1.875" x 1.5" x 3.064" Shipping case dimensions: 8" x 6.5" x 6.938" Each shipping case contains 32 cartons		CVS Specialty Pharmacy Phone: 866-526-4984 Fax: 855-592-6890 https://www.cvsspecialty.com/
Product Expiration	The expiration is printed on each vial and carton.		Orsini Specialty Pharmacy Phone: 888-221-4943 Fax: 847-892-1205 Email: OrsiniCareTeamISEMBYLD@orsinihc.com https://www.orsini.com/
Scholar Rock Supports™†	1-833-SRRK-444 (1-833-777-5444) Monday - Friday, 8 AM - 8 PM ET		CarePartners Pharmacy/ Seven Bridges Specialty Phone: 844-996-4840 Fax: 888-711-1081 https://www.carepartnersrx.com
Medical Information	Email: Medicalinformation@scholarrock.com Phone: 1-855-MED-SRRK		
Product Returns	1-877-663-9118		

NDC=National Drug Code; SMA=spinal muscular atrophy.

*For qualified entities only. Qualified entities for direct purchase include hospitals, physician practices, and institutions that have been licensed by a state agency to dispense and infuse pharmaceutical products to appropriate patients. Direct purchase is not available to retail pharmacies or specialty pharmacy providers who are not themselves part of a qualified entity. Eligible government entities include the Department of Defense (DoD), Department of Veterans Affairs, and 340B-covered entities.

†Ordering ISEMBYLD from sources outside of the listed specialty distributors and specialty pharmacy network may result in a delay or nonfulfillment of the prescription.

‡All patients are encouraged to enroll in Scholar Rock Supports for access to comprehensive patient support regardless of the procurement path of ISEMBYLD.

INDICATION

ISEMBYLD (apitegromab-mstn) is indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Fractures

ISEMBYLD may increase the risk of fractures, including serious fractures. Use with caution in patients with a history of low bone density or multiple fractures. In patients who experience fractures, weigh the risks and benefits of continuing ISEMBYLD.

Please see additional Important Safety Information on next page and full Prescribing Information.

IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

The most common adverse reactions (incidence $\geq 20\%$ of patients treated with ISEMBYLD and more frequent than placebo) were upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis, and hypersensitivity.

USE IN SPECIFIC POPULATIONS

Pregnancy and Lactation

Based on animal data, ISEMBYLD may cause fetal harm. There are no adequate data on the developmental risk associated with the use of ISEMBYLD in pregnant women.

There are no data on the presence of ISEMBYLD in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ISEMBYLD, and any potential adverse effects on the breastfed infant.

Females and Males of Reproductive Potential

Based on animal data, ISEMBYLD may affect male and/or female reproductive function.

Please see additional Important Safety Information on the previous page and full [Prescribing Information](#).

Reference: ISEMBYLD Prescribing Information. Scholar Rock, 2026.



ISEMBYLD is a trademark of Scholar Rock.
Scholar Rock © 2026. All rights reserved.
US-APIT-0047 09/26

ISEMBYLD™
(apitegromab-mstn) injection
150mg/3mL